Methcathinone (MCAT) and 2-methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (MDMCAT) inhibit [3H]serotonin uptake into human platelets
Nicholas V. Cozzi, Alexander T. Shulgin, and Arnold E. Ruoho
Amer. Chem. Soc. Div. Med. Chem. Abs., 1998; 215: 152


The benzylic ketone analogs of the psychoactive phenylisopropylamine methamphetamine (MA), MCAT, and of 3,4-methylenedioxymethamphetamine (MDMA), MDMCAT, were synthesized and compared to the nonketo compounds for their abilities to inhibit reuptake transporter-mediated [3H]serotonin accumulation into human platelets. MCAT inhibited [3H]serotonin uptake into platelets with an IC50 of 33.7 ± 9.0 mM while MA exhibited an IC50 of 11.7 ± 1.0 mM; this difference was not significant. The methylenedioxy-substituted compounds were about 6-fold more potent (p < 0.05) than the unsubstituted compounds in this assay; MDMCAT displayed an IC50 of 5.8 ± 0.7 mM and MDMA had an IC50 of 2.1 ± 0.3 mM. The difference in potency between MDMCAT and MDMA was significant at p < 0.01. These results indicate that beta-keto derivatization of psychoactive phenylalkylamines does not have a major impact on the drugs' ablility to inhibit serotonin uptake and that phenyl ring substitutions can enhance potency.

Alexander Shulgin
Methylone: structure
Methylone: metabolism
Methylone and the catecholamines
Does TFMPP + BZP mimic MDMA (Ecstasy)?
Methylone and monoamine neurotransmission

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family